Efficacy and Safety of 300 μg and 400 μg Cerivastatin Once Daily in Patients with Primary Hypercholesterolemia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study
| Autor: | Schmage N, Hanefeld M, Deslypere Jp, Durrington Pn, Ose L, Farnier M |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin Pyridines medicine.drug_class Hypercholesterolemia Placebo-controlled study Administration Oral Aspartate transaminase 030204 cardiovascular system & hematology Placebo 030226 pharmacology & pharmacy Biochemistry Gastroenterology 03 medical and health sciences 0302 clinical medicine Double-Blind Method Internal medicine Humans Medicine Adverse effect biology business.industry Biochemistry (medical) Cerivastatin Cell Biology General Medicine Middle Aged Endocrinology Alanine transaminase Toxicity biology.protein Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Journal of International Medical Research. 27:115-129 |
| ISSN: | 1473-2300 0300-0605 |
| DOI: | 10.1177/030006059902700302 |
| Popis: | This study examined the action of cerivastatin, a new statin, in subjects with primary hypercholesterolaemia. The effects of two oral doses of cerivastatin (400 micrograms/day or 300 micrograms/day) were compared with placebo in 349 patients using a multicentre, randomized, double-blind, placebo-controlled study design. Cerivastatin treatment lasted 8 weeks and produced significant reductions in low density lipoprotein-cholesterol (LDL-C) levels from baseline compared with placebo. The reduction in LDL-C was significantly greater with 400 micrograms than with 300 micrograms cerivastatin. When responder rates were examined, the higher (400 micrograms/day) cerivastatin dose was found to be more effective in producing larger (> 40%) reductions in LDL-C levels. Cerivastatin treatment was well tolerated. Only two withdrawals due to adverse events during active treatment occurred, neither of which was considered to be due to the study medication. In addition, no clinically relevant increases in the levels of creatine phosphokinase and hepatic transaminases (alanine transaminase and aspartate transaminase) compared with placebo were seen in this study. In conclusion, cerivastatin treatment produced a significant lowering of LDL-C levels, with the higher dose providing the greatest benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|